The first-month results on semaglutide typically show 3-5 pounds of loss, with the pace accelerating as doses increase
a 2026 analysis of seven trials put the average lean-mass loss around 1.74 kilograms, though as a share of a now-smaller body, lean mass actually rises (Laverde, International Journal of Obesity, 2026)
Helpful context before the funnel FormBlends Editorial Context Reviewed May 14, 2026 Retatrutide for Seniors Over 65
AstraZeneca has deliberately chosen not to directly compete in the GLP-1/GIP receptor agonist space a strategic choice that, while differentiating, leaves it without exposure to the highest-growth peptide market segment (65.8% of the peptide therapy market
If weight loss remains stalled longer, discuss dose optimization with your provider